Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.53 |
| ▸ | JAK1 | P23458 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 3/20 | 0.52 |
| ▸ | ACACA | Q13085 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30779591 | 1.00 | NPC1 (0.53) | NPC1RAB9AJAK2JAK1MEN1 | |
| SCHEMBL30779602 | 0.89 | SGMS2 (0.47) | MEN1KMT2AMET | |
| SCHEMBL21644625 | 0.89 | SGMS2 (0.47) | MEN1KMT2AMET | |
| SCHEMBL28414836 | 0.87 | JAK2 (0.53) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL30779601 | 0.83 | LRRK2 (0.48) | NPC1RAB9AMEN1KMT2AMAOB | |
| SCHEMBL21644588 | 0.83 | LRRK2 (0.48) | NPC1RAB9AMEN1KMT2AMAOB | |
| SCHEMBL21644687 | 0.82 | SGMS2 (0.62) | NPC1RAB9AMEN1KMT2AMET | |
| SCHEMBL30779582 | 0.82 | SGMS2 (0.62) | NPC1RAB9AMEN1KMT2AMET | |
| SCHEMBL21644614 | 0.81 | PABPC1 (0.53) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL30779645 | 0.81 | PABPC1 (0.53) | NPC1RAB9AMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479528-B2 | Heat shock protein 90 inhibitors | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-10-25 | — | — | US | disclosed |
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-02-06 | — | — | US | disclosed |
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | NPC1 1353/4885RAB9A 1972/4885JAK2 1032/4885 |
| US-11479528-B2 | Heat shock protein 90 inhibitors | HSP90AB1, HSP90AB2P, HSP90AA1 | NPC1 1353/4885RAB9A 1972/4885JAK2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.